In vitro diagnostics (IVD) is driving a new age shift in healthcare, fueled by advances in medical technology (medtech). These innovations are revolutionizing how diseases are detected, monitored, and managed. At the recent AdvaMed’s MedTech Conference in Toronto, digital and artificial intelligence (AI) integration, point-of-care (POC) testing, and novel biomarkers were emphasized as important tools in improving the precision and accessibility of medical care. The focus on these innovations will support disease detection, enable earlier diagnosis, personalized treatments, improve patient outcomes, and expand healthcare access, according to GlobalData, a leading data and analytics company.
Expert speakers at the conference this year emphasized the need to bridge the gap between patients and healthcare. Manufacturers like Hologic focused on the lack of cytologists, which leads to delays in cervical cancer screening. To address this, they created an AI-led platform that streamlines and identifies abnormal cell samples to save cytologists’ time.
Other companies like Solventum and GE Healthcare highlighted that AI can be utilized as an administration tool by helping medical professionals with patient notes and documentation, manufacturer inventory management, managing waste in manufacturing factories, and improving customer product delivery. The main factors considered for improving medical care are, how can we serve patients better, maximize healthcare professional (HCP) time and expertise, and doing all this with existing regulations.
Selena Yu, Senior Medical Analyst, at GlobalData, comments: “Decentralized testing is the key to improving patient access to care, detecting diseases earlier, and monitoring patients. These POC tests include over the counter (OTC) tests, direct-to-consumer (DTC) tests, and tests done at patient side, which are typically performed by non-HCPs. The seminar speakers stressed the ongoing issue of healthcare “deserts” and how expanding alternate care outside of doctor offices is crucial to reach these at-risk populations.”
The lack of reimbursement for POC tests remains a significant barrier, even though access to care is improved when individuals can buy STI tests at local pharmacies. Without reimbursement, however, this convenience adds another layer of inaccessibility. The overall goal for increased decentralized testing is to bridge the gap between patients and healthcare systems so that more individuals are aware of their health status.
Moreover, experts in the IVD sector—including manufacturers, laboratories, and investors—highlighted key markets for future growth at AdvaMed’s MedTech Conference. The major focus areas included women’s health, neurology, autoimmunity, minimal residual disease, sepsis, and cancer screening especially liquid biopsy. Both speakers and attendees stressed the importance of clinical utility in developing IVDs, emphasizing the need for test results to be actionable, for appropriate actions to be taken based on those results, and for these actions to ultimately improve patient outcomes.
Yu concludes: “Innovation in IVD is growing particularity in digital and AI integration into healthcare, POC testing, and novel biomarkers. This will aid in disease detection, monitoring, and management, enabling earlier diagnosis, personalized treatments, improving patient prognosis, and increasing patient access to healthcare.”
